Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Sanofi, Formation Bio and OpenAI have joined forces to build ... “At scale, this AI-driven development approach can ...

PARIS, Oct 16 (Reuters) - French unions have called on workers at Sanofi (SASY.PA), opens new tab to strike from Thursday to protest a planned sale of the pharmaceutical group's consumer health ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&R have entered exclusive negotiations for the ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

Please find enclosed a copy of the Postal Ballot Notice together with the Explanatory Statement for your record. We have also enclosed the Calendar of Events for the Postal Ballot process for your ...

Sanofi could announce the deal with buyout firm CD&R as soon as early next week, according to the people. The consumer health unit, known as Opella, is set to be valued at around €15 billion ...